Sort
326,823 grants matching “clinical trial”
TUMOR HYPOXIA--MOLECULAR STUDIES &CLINICAL EXPLOITATION
$1,584,418Stanford University · P01 · FY2000 · CA
Physicians' Health Study II: Prevention Trial of Vitamins
$1,584,282J Michael Gaziano · Brigham And Women'S Hospital · R01 · FY2011 · CA
Development of a human hepatocyte predictive pharmacology and toxicology system.
$1,584,146Brian Robert Wamhoff · Hemoshear Therapeutics, Llc · R44 · FY2013 · DK
Anti-Fibrotic Therapy for Scleroderma/SSc
$1,584,102Latha Paka · Angion Biomedica Corporation · R44 · FY2014 · AR
Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain
$1,584,065Ardith Z Doorenbos · University Of Illinois At Chicago · UH3 · FY2024 · AT
Development of Toll-Like Receptor Agonists as Neuroprotectants in Brain Ischemia
$1,584,063Mary P Stenzel-Poore · Oregon Health & Science University · U01 · FY2011 · NS
Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction (EPISOD)
$1,584,047Peter B Cotton · Medical University Of South Carolina · U01 · FY2011 · DK
HEAL Initiative: Research to Foster an Opioid Use Disorder Treatment System Patients Can Count On
$1,583,828Tami L Mark · Research Triangle Institute · RM1 · FY2025 · DA
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
$1,583,667Katherine N Cahill · Vanderbilt University Medical Center · U01 · FY2023 · AI
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
$1,583,667Katherine N Cahill · Vanderbilt University Medical Center · U01 · FY2025 · AI
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
$1,583,667Katherine N Cahill · Vanderbilt University Medical Center · U01 · FY2021 · AI
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
$1,583,667Katherine N Cahill · Vanderbilt University Medical Center · U01 · FY2024 · AI
Glucagon-Like Peptide-1 Receptor Agonist Treatment in Adult, Obesity-Related, Symptomatic Asthma
$1,583,667Katherine N Cahill · Vanderbilt University Medical Center · U01 · FY2022 · AI
Epidemiology, Pathophysiology and Treatment of Diabetic Nephropathy
$1,583,359Robert G Nelson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
Nebraska Pediatric Clinical Trial Unit
$1,583,355Russell James McCulloh · University Of Nebraska Medical Center · UG1 · FY2016 · OD
Pragmatic Trial of Population-based Programs to Prevent Suicide Attempt
$1,583,353Gregory E Simon · Kaiser Foundation Health Plan Of Washington · UH3 · FY2016 · MH
Specialized Program of Translational Research In Acute Stroke at the Partners
$1,583,315Karen L. Furie · Massachusetts General Hospital · P50 · FY2008 · NS
Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC-DCC)
$1,583,252Liang Li · University Of Tx Md Anderson Can Ctr · U01 · FY2025 · DK
FOcal Cerebral Arteriopathy Steroids (FOCAS) Trial
$1,583,157Heather J Fullerton · University Of California, San Francisco · UH3 · FY2024 · NS
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)
$1,582,885Adeline Lucie Vanderver · Children'S Hosp Of Philadelphia · U54 · FY2019 · NS
New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae
$1,582,840Denis Marc Daigle · Venatorx Pharmaceuticals, Inc. · R01 · FY2023 · AI
Defining New Human Immunodeficiency and Immunodysregulation Disorders
$1,582,773Helen Su · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
$1,582,740Steven E Shoelson · Joslin Diabetes Center · U01 · FY2008 · DK
Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN
$1,582,668Edward M Newman · Beckman Research Institute/City Of Hope · UM1 · FY2019 · CA
Investigations of Methylmalonic Acidemia and Related Disorders
$1,582,664Charles P Venditti · National Human Genome Research Institute · ZIA · FY2015 · HG